DelveInsight's,“ Advanced Melanoma Pipeline Insight 2025 ” report provides comprehensive insights about 55+ companies and 60+ pipel ...

Under the Trump administration, the Department of Health and Human Services has canceled or frozen billions of ...

Rocket Pharmaceuticals, Inc.’s (NASDAQ:RCKT) prospects have taken a significant hit on the company being forced to halt ...

Petrova was charged with smuggling earlier this month as U.S. District Judge Christina Reiss in Burlington set the hearing ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The “first sale rule” is a concept in U.S. customs law that allows importers to use the lowest cost of a good to calculate ...

LOS ANGELES] Venture-backed startups are staying private for longer – and growing so much bigger – that they are starting to ...

IO Biotech (NASDAQ:IOBT) has filed for the sale of up to 5.6M shares of common stock for holders. Filing IO Biotech GAAP EPS of -$0.34 beats by $0.11 Seeking Alpha’s Quant Rating on IO Biotech Financi ...

Explore how CRISPR could become a powerful antiviral tool against HIV, Hepatitis B, HPV, and more, based on emerging research.

Google showcased the Gemini 2.5 PRO model at Google IO 2025. They previously released beta versions of GEmini2.5 Pro and ...

IO Biotech Inc. research and ratings by Barron's. View IOBT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines ...